The telehealth company Hims & Hers Health is accelerating its international growth strategy, with a new launch in the United Kingdom marking its latest move. This follows closely on the heels of its ...
For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...
The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...
Hims reports that 70% of Americans believe an economic downturn encourages healthier habits, like cooking at home and ...
A stark divergence is emerging at telehealth provider Hims & Hers. The company is aggressively pursuing operational expansion, yet this stands in sharp c ...
Insiders have been trading these 5 stocks: (($DELL)), (($HIMS)), (($U)), (($TMUS)) and (($LUV)). Here is a breakdown of their recent trades and ...
2d
Navigating Regulatory Headwinds: Hims & Hers Balances Growth Ambitions with Legislative Challenges
Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...
HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to ...
Zacks Investment Research on MSN
Investors heavily search Hims & Hers Health, Inc. (HIMS): Here is what you need to know
Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...
Amgen AMGN announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication — generalized myasthenia gravis (gMG). The drug is approved to treat the disease in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback